Previous 10 | Next 10 |
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx Addition of Talicia® by OptumRx significantly extends Commercial patient access to Talicia® through this leader in U.S. healthcare Patient access to Talicia now ...
RedHill's downbeat share trajectory is testing shareholder patience as its catalysts are slow to develop. RedHill's FDA approved therapies, Talicia and its Aemcolo, are both stalled at the starting gate. MOVANTIK revenues are coming in nicely and provide financial support while la...
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual anti...
RedHill Biopharma (RDHL) perks up 4.4% premarket after announcing that all treatment and follow-up has now been completed in the 475-patient Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia.Top-line results are expected in t...
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual an...
You can read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The earnings season heats up in a big way next week with IBM (NYSE:IBM), Netflix (NASDAQ:NFLX), Chipotle (NYSE:CMG), Coc...
solarseven/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
Shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) traded at a new 52-week low today of $5.90. This new low was reached on below average trading volume as 103,000 shares traded hands, while the average 30-day volume is approximately 278,000 shares. In the past 52 weeks, Redhill Biopharma Ltd...
RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans Movantik® included as preferred brand with no restrictions on a National Formulary of one of America's largest payors as of Ju...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...